Maryland Reporter: All non-essential businesses must close by 5 p.m. on March 23, Hogan orders

Gov. Larry Hogan issued an executive order to close all non-essential businesses in order to control the spread of the coronavirus.

Centrexion President to speak at GBC Bioscience meeting

Centrexion President and Chief Scientific Officer Dr. James Campbell will present during the GBC Bioscience Committee meeting at 8:15 a.m. Thursday, July 24. Centrexion is a Baltimore biotech company launched late 2013, which has raised $23.4 million in funds for its products, according to the Baltimore Business Journal. Campbell is the founder and CEO of Canton biotech company Arcion, which developed a topical gel to treat chronic pain. Additionally, he … Continue reading

Forest City launches new site to showcase science park at Hopkins

  Last week, Forest City Science+Technology Group launched a new Web site to showcase the science and people at the Science + Technology Park at Johns Hopkins. Each tenant at the park has their own page, which are consolidated on an interactive page. Video features have been created and embedded on various pages, and video clips from Cureveda, Lieber Institute for Brain Development, Inostics and BioMarker Strategies are available for … Continue reading

Gliknik raises $4.9 million in Series B financing

  Gliknik Inc., a privately-held biopharmaceuticals company creating new therapies for cancer and immune/inflammatory disorders, announced on October 22 it has raised $4.9 million in Series B Financing. Baxter Ventures, an initiative created in 2011 by Baxter International Inc., led the Series B raise and is joined by existing investors. With the funding, Gliknik will further advance toward the clinic its IVIG-mimetic lead compound, GL-2045, from its first-in-class stradomer platform. … Continue reading

BmoreMedia: Biotech firm Fyodor to begin trials for malaria test

  Fyodor Biotechnology Inc. expects to complete human trials on its product to detect malaria next year, with commercial production to begin in 2014. The Baltimore biotech firm is also in the planning stages for a second product, a variation of the first, that should be ready for production by 2015. The tests are significant for diagnosis and treatment of an illness that is endemic in developing countries around the … Continue reading

Fyodor Biotechnologies expands within University of Maryland BioPark

  Fyodor Biotechnologies Inc. announced on August 16 it has expanded its office and laboratory space at the University of Maryland BioPark in Baltimore, moving from the BioPark’s BioInnovation Center (BIC) at 801 West Baltimore Street to the expanded BioInnovation Center across the street at 800 West Baltimore Street. The move is prompted by Fyodor’s advancing research and development activities, including those related to its urine-based malaria diagnostic assay. “The … Continue reading

JHU and Fraunhofer Heinrich Hertz Institute team up

  The Johns Hopkins University (JHU), America’s first research university, in Baltimore, Md., and the Fraunhofer Heinrich Hertz Institute (HHI), a mobile and information technology development leader based in Berlin, Germany, have signed a Memorandum of Understanding to jointly research the innovative medical applications of integrated optical sensors: small, highly sensitive devices with disease-recognition capabilities. Under the terms of this agreement – signed on June 19 at the 2012 BIO … Continue reading

Noxilizer wins best life sciences company award

  Noxilizer, located at the UMBC Technology Center, won Best Life Sciences Company in the Maryland Incubator Company of the Year awards. The award, announced at the Center Club June 14, recognizes the best company involved in biotechnolgy or life sciences industry. Chosen among three finalists, Noxilizer has a unique and superior NO2-based sterilization technology that is revolutionizing two major sterilization markets – medical device/pharmaceutical/biotechnology manufacturing and hospitals, according to … Continue reading

New York Times: Drug Helps Defense System Fight Cancer

  By ANDREW POLLACKPublished: June 1, 2012 CHICAGO – One of the great frustrations for researchers in the war on cancer is that the body’s own defense system does not do a better job fighting the disease. Tumors, it turns out, have a molecular shield that repels attacks from the immune system. Now, a new study says, an experimental drug is showing promise in disabling that shield, unleashing the immune … Continue reading

Profectus receives grant to develop vaccine for Nipah and Hendra viruses

Profectus BioSciences, Inc. (Profectus), a leader in the development of therapeutic and preventive vaccines against infectious diseases and cancers, announced May 2 it received a grant under the Partnerships for Biodefense RFA from the Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH. This $5.6M award supports the preclinical development of Hendra virus soluble G (HeV?sG) as a vaccine for use in humans against either … Continue reading